Skip to main content
Back
BEAM logo

Beam Therapeutics Inc.

Data quality: 100%
BEAM
NASDAQ Healthcare Biotechnology
$25.17
▲ $0.54 (2.19%)
Mkt Cap: 2.56B
Day Range
$24.97 $25.76
52-Week Range
$13.53 $36.44
Volume
1,168,056
50D / 200D Avg
$28.35 / $23.72
Prev Close
$24.63

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -32.1 0.4
P/B 2.1 2.9
ROE % -8.1 3.8
Net Margin % -57.2 3.9
Rev Growth 5Y % 28.1 10.0
D/E 0.2 0.2

Analyst Price Target

Hold
$40.86 +62.3%
Low: $26.00 High: $74.00
Forward EPS
-$4.36
Est. Revenue
45 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 -$1.27
-$2.98 – -$0.27
 710 M 4
FY2029 -$3.23
-$7.60 – -$0.68
 410 M 4
FY2028 -$4.65
-$7.93 – -$2.94
 140 M 10

Key Takeaways

Revenue grew 28.13% annually over 5 years — strong growth
Debt/Equity of 0.24 — conservative balance sheet
Negative free cash flow of -360.05M
PEG of 0.42 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 91.88%

Growth

Revenue Growth (5Y)
28.13%
Revenue (1Y)120.01%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-8.11%
ROIC-18.78%
Net Margin-57.24%
Op. Margin-274.57%

Safety

Debt / Equity
0.24
Current Ratio13.09
Interest Coverage-8.77

Valuation

P/E Ratio
-32.05
P/B Ratio2.07
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 120.01% Revenue Growth (3Y) -39.17%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 28.13% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 139.74M Net Income (TTM) -79.99M
ROE -8.11% ROA -5.40%
Gross Margin 84.05% Operating Margin -274.57%
Net Margin -57.24% Free Cash Flow (TTM) -360.05M
ROIC -18.78% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.24 Current Ratio 13.09
Interest Coverage -8.77 Dividend Yield 0.00%
Valuation
P/E Ratio -32.05 P/B Ratio 2.07
P/S Ratio 18.35 PEG Ratio 0.42
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.56B Enterprise Value 2.56B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 139.74M 63.52M 377.71M 60.92M 51.84M
Net Income -79.99M -376.74M -132.53M -289.09M -370.64M
EPS (Diluted) -0.81 -4.58 -1.72 -4.13 -5.77
Gross Profit 117.45M -304.04M 377.71M -250.67M -180.29M
Operating Income -383.69M -415.57M -176.49M -338.48M -392.47M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.48B 1.10B 1.46B 1.34B 1.47B
Total Liabilities 242.82M 370.28M 478.39M 608.24M 647.72M
Shareholders' Equity 1.24B 733.55M 981.33M 733.47M 826.74M
Total Debt 293.88M 161.43M 172.69M 179.01M 147.64M
Cash & Equivalents 294.94M 281.97M 435.90M 232.77M 559.99M
Current Assets 1.27B 878.15M 1.21B 1.09B 1.27B
Current Liabilities 96.94M 182.07M 205.57M 223.60M 213.44M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#34 of 146
60

Recent Activity

Entered Full Throttle
Mar 24, 2026